A Phase 3 interventional study of Generic Azelaic Acid Foam and Finacea® (Azelaic Acid) Foam in Rosacea, sponsored by Actavis Inc.. Completed at 26 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-07-31.
Sponsored by Actavis Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 146 studies in Rosacea with a site in United States — 10 open to participants now, 11 under way, none of them phase 3. Rosacea · United States.
Among the 146 studies in Rosacea with a site in United States, this one is the 7th largest by enrollment of the 138 interventional ones that give a count, is one of 8 that started in 2016, is one of 32 in phase 3, and was the 94th registered.
234 studies on the registry are indexed under Rosacea; 24 are open to participants now.
Browse Rosacea studies →10 of the 146 studies in Rosacea with a site in United States are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States, Bulgaria, Canada and 6 more countries
Ages 18+
Brigham and Women's Hospital · Sites in United States
Ages 18+
Narrows Institute for Biomedical Research · Sites in United States
Ages 18+ · Healthy volunteers
University of Miami · Sites in United States
Ages 18+
Wright State University · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 17 Rosacea studies recruiting now, 10 (59%) set no upper age limit and 6 (35%) stop at 75 or younger; 2 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
146 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 44 · Phase 3 34 · Phase 4 20
First in 2002; this study’s year is marked. 8 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 924 is above the median of 61 across 201 interventional studies indexed under Rosacea.
Median enrollment 74 across the 138 interventional studies, 236 across the 8 observational. Of the 127 that completed or were terminated, 76 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
99 of 146 have an industry lead sponsor. The 10 most frequent:
This study is registered under Actavis Inc., one of the names counted as Teva Pharmaceutical Industries, Ltd.. Under that name alone:
Actavis Inc. is the lead sponsor of 95 studies on the registry; none are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 10 (91%) have results posted.
Teva Pharmaceutical Industries, Ltd. has 5 studies filed under Rosacea — fewer than ten, so there is no comparison to draw.
4 of the studies in Rosacea with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07443202Tarsus Pharmaceuticals, Inc.Study of Lotilaner Ophthalmic Gel in Patients With Ocular Rosacea (KORE) | 2026-12-31 |
| NCT07946250BrocShot IncA Clinical Trial to Evaluate the Effects of Broc Shot Capsules on Skin Appearance and Comfort in Adults With Reactive, Blemish-Prone, or Hormonally Affected Skin | 2027-01 |
| NCT06801717University of MiamiRosacea Radiofrequency Microneedling | 2027-07-01 |
| NCT04108897Johns Hopkins UniversityAnalysis of the Microbiome in Rosacea | 2027-09 |
Add all 4 to your calendar (.ics) → With an account.
Among the 146 studies in Rosacea with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objectives of this study were to compare the safety and efficacy profiles of a generic Azelaic Acid Foam, 15% to the reference listed Finacea® (azelaic acid) Foam, 15% and to demonstrate therapeutic equivalence and safety of the two active foams in the treatment of moderate facial rosacea, and to demonstrate superiority of the Reference and Test products over the Vehicle.
Topical azelaic acid is used to treat inflammatory papules and pustules of mild to moderate rosacea. Other topical therapies and oral antibiotics are also used to treat rosacea symptoms. Finacea® (azelaic acid) Foam, 15% contains azelaic acid, a naturally occurring saturated dicarboxylic acid that has proven anti-inflammatory effects, as well as anti-keratinizing and antimicrobial actions.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The use within 1 month prior to baseline of the following:
Use within two weeks prior to baseline of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A thin layer of generic azelaic acid, 15% topical foam was to be gently massaged into the entire facial area twice daily, once in the morning and once in the evening, for 12 weeks. Contact with the mouth, eyes, and other mucous membranes was to be avoided. Hands were to be washed following application of study drug. Participants were instructed not to bathe, shower, wash, or swim for at least 4 hours after application of study drug. Participants were provided with mild cleanser, a towel, sunscreen, and moisturizing lotion to be used on treated areas while participating in the study.
Drug: Generic Azelaic Acid Foam · Other: Cleanser · Other: Sunscreen · Other: Towel · Other: Moisturizing Lotion
A thin layer of Finacea (azelaic acid), 15% topical foam was to be gently massaged into the entire facial area twice daily, once in the morning and once in the evening, for 12 weeks. Contact with the mouth, eyes, and other mucous membranes was to be avoided. Hands were to be washed following application of study drug. Participants were instructed not to bathe, shower, wash, or swim for at least 4 hours after application of study drug. Participants were provided with mild cleanser, a towel, sunscreen, and moisturizing lotion to be used on treated areas while participating in the study.
Drug: Finacea® (Azelaic Acid) Foam · Other: Cleanser · Other: Sunscreen · Other: Towel · Other: Moisturizing Lotion
A thin layer of the vehicle topical foam was to be gently massaged into the entire facial area twice daily, once in the morning and once in the evening, for 12 weeks. Contact with the mouth, eyes, and other mucous membranes was to be avoided. Hands were to be washed following application of study drug. Participants were instructed not to bathe, shower, wash, or swim for at least 4 hours after application of study drug. Participants were provided with mild cleanser, a towel, sunscreen, and moisturizing lotion to be used on treated areas while participating in the study.
Drug: Vehicle Foam · Other: Cleanser · Other: Sunscreen · Other: Towel · Other: Moisturizing Lotion
Topical foam, generic formulation of the brand product.
Topical foam, brand product.
Topical foam, placebo. Has no active ingredient.
A mild cleanser provided to participants, so they can wash their face prior to applying the study drug.
Sunscreen provided to participants, so they can apply it to their face when outdoors.
A soft towel provided to participants, so they can pat their face dry after washing and prior to applying the study drug.
Moisturizing lotion provided to participants, so they can apply it to their face, as needed.
Percent Change From Baseline in the Inflammatory Lesions (Papules and Pustules) Counts at Week 12
All facial papules, pustules, and nodules, located above the jaw line and extending to the hairline, were counted. When counting facial lesions, lesions present on the nose were included. The total count for each lesion type was recorded and the total number of inflammatory lesions (papules and pustules) were calculated. A papule with a pustule on its apex was counted as a pustule. Counts of nodules and cysts were reported separately and not included in the inflammatory counts. Papule defined as inflammatory lesion; small (≤5 mm in diameter), solid palpable lesion, usually with inflamed elevation of the skin that does not contain pus. Pustule defined as inflammatory lesion; small (≤5 mm in diameter), inflamed skin swelling that is filled with pus. Cyst and nodule defined as palpable solid or soft lesion \>5 mm in diameter.
Time frame: Baseline, 12 weeks
Percentage of Participants With Treatment Success Based on IGE Score
Treatment success defined as an Investigator's Global Evaluation (IGE) score at Week 12 of 0 (clear) or 1 (almost clear). Any other outcome was considered a failure. Participants who were discontinued prematurely from the study due to lack of treatment effect after at least 8 weeks of compliant treatment were considered as treatment failures. The IGE score was based on a 5-point scale ranging from 0 to 4 (0=clear, 1=almost clear, 2=mild, 3=moderate, and 4=severe).
Time frame: Baseline and 12 Weeks
The populations for this study included the Safety Population, the modified Intent-to-Treat (mITT) population, and the Per-Protocol (PP) Population.
| Milestone | Generic Azelaic Acid Foam | Finacea (Azelaic Acid) Foam | Vehicle Foam |
|---|---|---|---|
| Started | 312 | 312 | 300 |
| Safety population | 306 | 297 | 291 |
| Mitt population | 291 | 291 | 283 |
| Pp population | 262 | 259 | 245 |
| Completed | 280 | 276 | 264 |
| Not completed | 32 | 36 | 36 |
| Withdrew: Insufficient therapeutic response | 0 | 0 | 1 |
| Withdrew: Adverse event | 0 | 4 | 3 |
| Withdrew: Withdrawal by subject | 12 | 12 | 17 |
| Withdrew: Missed more than 6 consecutive doses | 3 | 2 | 2 |
| Withdrew: Lost to follow-up | 8 | 14 | 11 |
| Withdrew: Protocol violation | 7 | 2 | 1 |
| Withdrew: Participant was enrolled at 2 sites | 1 | 0 | 1 |
| Withdrew: Too much time between 2 visits | 0 | 1 | 0 |
| Withdrew: Non-compliance | 0 | 1 | 0 |
| Withdrew: Did not meet inclusion criteria | 1 | 0 | 0 |
All facial papules, pustules, and nodules, located above the jaw line and extending to the hairline, were counted. When counting facial lesions, lesions present on the nose were included. The total count for each lesion type was recorded and the total number of inflammatory lesions (papules and pustules) were calculated. A papule with a pustule on its apex was counted as a pustule. Counts of nodules and cysts were reported separately and not included in the inflammatory counts. Papule defined as inflammatory lesion; small (≤5 mm in diameter), solid palpable lesion, usually with inflamed elevation of the skin that does not contain pus. Pustule defined as inflammatory lesion; small (≤5 mm in diameter), inflamed skin swelling that is filled with pus. Cyst and nodule defined as palpable solid or soft lesion \>5 mm in diameter.
| percent change | Generic Azelaic Acid Foam | Finacea (Azelaic Acid) Foam | Vehicle Foam |
|---|---|---|---|
| Percent Change From Baseline in the Inflammatory Lesions (Papules and Pustules) Counts at Week 12 | -64.28 ± 25.050 | -65.15 ± 26.419 | -57.84 ± 30.626 |
Treatment success defined as an Investigator's Global Evaluation (IGE) score at Week 12 of 0 (clear) or 1 (almost clear). Any other outcome was considered a failure. Participants who were discontinued prematurely from the study due to lack of treatment effect after at least 8 weeks of compliant treatment were considered as treatment failures. The IGE score was based on a 5-point scale ranging from 0 to 4 (0=clear, 1=almost clear, 2=mild, 3=moderate, and 4=severe).
| percentage of participants | Generic Azelaic Acid Foam | Finacea (Azelaic Acid) Foam | Vehicle Foam |
|---|---|---|---|
| Percentage of Participants With Treatment Success Based on IGE Score | 39.7 | 48.3 | 33.5 |
Collected over Baseline up to Day 84. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Generic Azelaic Acid Foam | 0/306 (0%) | 0/306 (0%) | 129/306 (42.2%) |
| Finacea (Azelaic Acid) Foam | 0/297 (0%) | 2/297 (0.7%) | 128/297 (43.1%) |
| Vehicle Foam | 0/291 (0%) | 1/291 (0.3%) | 125/291 (43%) |
| Event | Generic Azelaic Acid Foam | Finacea (Azelaic Acid) Foam | Vehicle Foam |
|---|---|---|---|
| HypocalcaemiaEndocrine disorders | 0/306 | 0/297 | 1/291 |
| Prostate cancerRenal and urinary disorders | 0/306 | 1/297 | 0/291 |
| CellulitisImmune system disorders | 0/306 | 1/297 | 0/291 |
| Event | Generic Azelaic Acid Foam | Finacea (Azelaic Acid) Foam | Vehicle Foam |
|---|---|---|---|
| Application site drynessGeneral disorders | 45/306 | 29/297 | 52/291 |
| Application site pruritusGeneral disorders | 51/306 | 43/297 | 28/291 |
| Application site painGeneral disorders | 47/306 | 41/297 | 28/291 |
| Application site erythemaGeneral disorders | 30/306 | 28/297 | 34/291 |
| Application site reactionGeneral disorders | 22/306 | 19/297 | 20/291 |
| HeadacheNervous system disorders | 15/306 | 9/297 | 12/291 |
| Application site swellingGeneral disorders | 2/306 | 6/297 | 8/291 |
| InfluenzaInfections and infestations | 6/306 | 0/297 | 2/291 |
| Application site oedemaGeneral disorders | 3/306 | 4/297 | 5/291 |
| SinusitisInfections and infestations | 1/306 | 5/297 | 0/291 |
Randomized participants with evidence in diary card of using ≥1 dose of study drug (Safety Population).
| Age, Continuous(years) | Generic Azelaic Acid Foam | Finacea (Azelaic Acid) Foam | Vehicle Foam | Total |
|---|---|---|---|---|
| Mean | 51.6 ± 14.20 | 52.3 ± 15.14 | 51.0 ± 15.09 | 51.6 ± 14.80 |
| Sex: Female, Male(Participants) | Generic Azelaic Acid Foam | Finacea (Azelaic Acid) Foam | Vehicle Foam | Total |
|---|---|---|---|---|
| Female | 212 | 220 | 204 | 636 |
| Male | 94 | 77 | 87 | 258 |
| Ethnicity (NIH/OMB)(Participants) | Generic Azelaic Acid Foam | Finacea (Azelaic Acid) Foam | Vehicle Foam | Total |
|---|---|---|---|---|
| Hispanic or Latino | 185 | 177 | 180 | 542 |
| Not Hispanic or Latino | 121 | 120 | 111 | 352 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Generic Azelaic Acid Foam | Finacea (Azelaic Acid) Foam | Vehicle Foam | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 4 | 4 | 3 | 11 |
| White | 302 | 292 | 288 | 882 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Inflammatory Lesion Count(inflammatory lesions) | Generic Azelaic Acid Foam | Finacea (Azelaic Acid) Foam | Vehicle Foam | Total |
|---|---|---|---|---|
| Mean | 17.1 ± 8.85 | 16.7 ± 7.88 | 17.7 ± 8.88 | 17.1 ± 8.55 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2016 to primary completion in Jun 2017, 11 months.
Results were first posted in Jul 2019, 2 years after primary completion.
Of 17 phase 3 interventional studies under Rosacea, half reached primary completion within 11 months of starting (the median); a quarter within 9 and three quarters within 15. This study's 11 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.